A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis-Reference-Cited by-同舟云学术

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

Published:2015-07-30 Issue:5 Volume:126 Page:612-615
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Palladini Giovanni¹,Sachchithanantham Sajitha²,Milani Paolo¹,Gillmore Julian²,Foli Andrea¹,Lachmann Helen²,Basset Marco¹,Hawkins Philip²,Merlini Giampaolo¹,Wechalekar Ashutosh D.²

Affiliation:

1. Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy; and

2. National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom

Abstract

Key Points CyBorD achieves excellent outcome in noncardiac patients with AL amyloidosis and can rescue subjects with reversible heart damage. The outcome of high-risk patients remains poor, but response to CyBorD can also improve survival in this group.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/5/612/1391539/612.pdf

Reference23 articles.

1. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.;Bianchi;Blood,2009

2. Bortezomib in the treatment of AL amyloidosis: targeted therapy?;Sitia;Haematologica,2007

3. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.;Kastritis;J Clin Oncol,2010

4. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.;Reece;Blood,2014

5. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.;Venner;Blood,2012

Cited by 335 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024;The Journal of Heart and Lung Transplantation;2024-10

2. Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis;ESC Heart Failure;2024-08-31

3. Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system;American Journal of Hematology;2024-08-29

4. A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots;Frontiers in Medicine;2024-07-30

5. Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab;Journal of Clinical Medicine;2024-07-14